Ahmed Megahed1,2, Nanees Salem3,2, Abeer Fathy4,5, Tarik Barakat1,2, Mona Abd El Latif Alsayed1,2, Suzy Abd El Mabood6,2, Khaled R Zalata7, Ahmed F Abdalla1,2. 1. Pediatric Gastroenterology and Hepatology Unit, Mansoura University Children's Hospital, Al Gomhoria Street, Mansoura, Egypt. 2. Faculty of Medicine, Mansoura University, Mansoura, Egypt. 3. Pediatric Endocrinology Unit, Mansoura University Children's Hospital, Mansoura, Egypt. 4. Pediatric Gastroenterology and Hepatology Unit, Mansoura University Children's Hospital, Al Gomhoria Street, Mansoura, Egypt. abeerfathy2000@yahoo.com. 5. Faculty of Medicine, Mansoura University, Mansoura, Egypt. abeerfathy2000@yahoo.com. 6. Pediatric Hematology & Oncology Unit, Mansoura University Children's Hospital, Mansoura, Egypt. 7. Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Abstract
BACKGROUND: The impact of chronic hepatitis C (CHC) on bone mineral density (BMD) has been well studied in adults with a relative paucity of data in children, especially concerning effect of treatment with pegylated interferon (PEG-IFN) plus ribavirin (RV). In the current work, we assessed prospectively changes in BMD in children with CHC before, during, and after treatment. METHODS: Forty-six consecutive children with noncirrhotic genotype 4 CHC were subjected to dual-energy X-ray absorptiometry at baseline, 24 weeks, 48 weeks of therapy and 24 weeks after treatment. BMD, bone mineral content (BMC), and Z score of lumbar spine (L2-L4) were reported. Tanner pubertal stage, viral load, liver function tests, serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone, and liver histopathology were assessed in all included children. RESULTS: Thirty (65.2%) patients had normal BMD, 10 (21.7%) were at risk for low BMD, and 6 (13.1%) had low BMD for chronological age. Patients with low BMD were significantly older (P=0.001), with higher frequency of delayed puberty than other groups (P=0.002). Baseline densitometric parameters (BMD & BMC) were significantly positively correlated with patients' age, weight, height, body mass index and hemoglobin level; while they were insignificantly correlated with basal viral load, histopathology activity index and fibrosis score. Densitometric parameters improved significantly on PEG-IFN plus RV treatment, this improvement was found to be sustainable 24 weeks after therapy. CONCLUSIONS: Low BMD is detectable in a proportion of CHC children. Antiviral therapy leads to a sustainable increase in BMD.
BACKGROUND: The impact of chronic hepatitis C (CHC) on bone mineral density (BMD) has been well studied in adults with a relative paucity of data in children, especially concerning effect of treatment with pegylated interferon (PEG-IFN) plus ribavirin (RV). In the current work, we assessed prospectively changes in BMD in children with CHC before, during, and after treatment. METHODS: Forty-six consecutive children with noncirrhotic genotype 4 CHC were subjected to dual-energy X-ray absorptiometry at baseline, 24 weeks, 48 weeks of therapy and 24 weeks after treatment. BMD, bone mineral content (BMC), and Z score of lumbar spine (L2-L4) were reported. Tanner pubertal stage, viral load, liver function tests, serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone, and liver histopathology were assessed in all included children. RESULTS: Thirty (65.2%) patients had normal BMD, 10 (21.7%) were at risk for low BMD, and 6 (13.1%) had low BMD for chronological age. Patients with low BMD were significantly older (P=0.001), with higher frequency of delayed puberty than other groups (P=0.002). Baseline densitometric parameters (BMD & BMC) were significantly positively correlated with patients' age, weight, height, body mass index and hemoglobin level; while they were insignificantly correlated with basal viral load, histopathology activity index and fibrosis score. Densitometric parameters improved significantly on PEG-IFN plus RV treatment, this improvement was found to be sustainable 24 weeks after therapy. CONCLUSIONS: Low BMD is detectable in a proportion of CHCchildren. Antiviral therapy leads to a sustainable increase in BMD.
Entities:
Keywords:
bone mineral density; chronic hepatitis C; pegylated interferon; ribavirin
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Claudia Helena Bastos da Silva Alves; Hilton Kuperman; Vaê Dichtchekenian; Durval Damiani; Thais Della Manna; Lilian Maria Cristófani; Vicente Odone Filho; Nuvarte Setian Journal: Rev Hosp Clin Fac Med Sao Paulo Date: 2004-04-26
Authors: Sara Cuesta-Sancho; Mercedes Márquez-Coello; Francisco Illanes-Álvarez; Denisse Márquez-Ruiz; Ana Arizcorreta; Fátima Galán-Sánchez; Natalia Montiel; Manuel Rodriguez-Iglesias; José-Antonio Girón-González Journal: World J Hepatol Date: 2022-01-27